-
EP3345925
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3345925
| EP3345925 - HUMANIZED ANTIBODIES TARGETING THE EC1 DOMAIN OF CADHERIN-11 AND RELATED COMPOSITIONS AND METHODS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 26.07.2019 Database last updated on 28.06.2024 | |
| Former | The application has been published Status updated on 08.06.2018 | Most recent event Tooltip | 26.07.2019 | Application deemed to be withdrawn | published on 28.08.2019 [2019/35] | Applicant(s) | For all designated states Adheron Therapeutics, Inc. 1 DNA Way, MS 24 South San Francisco, CA 94080 / US | [2018/28] | Inventor(s) | 01 /
MCARTHUR, James, G. 95 Conant Street 311 Concord, MA 01742 / US | [2018/28] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2018/28] | Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | Application number, filing date | 17203400.1 | 15.07.2011 | [2018/28] | Priority number, date | US20100364698P | 15.07.2010 Original published format: US 364698 P | [2018/28] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP3345925 | Date: | 11.07.2018 | Language: | EN | [2018/28] | Type: | A3 Search report | No.: | EP3345925 | Date: | 26.09.2018 | Language: | EN | [2018/39] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 23.08.2018 | Classification | IPC: | C07K16/28, A61K39/395, A61P29/00 | [2018/28] | CPC: |
A61P13/02 (EP);
C07K16/28 (EP,CN,KR,US);
C07K16/461 (CN,US);
A61K39/39541 (US);
A61K39/3955 (CN,KR,US);
A61K45/06 (CN,US);
A61P17/00 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P25/00 (EP);
A61P29/00 (EP);
A61P35/00 (EP);
A61P37/02 (EP);
A61P37/06 (EP);
A61P43/00 (EP);
C07K14/461 (KR);
A61K2039/505 (EP,CN,US);
C07K2317/21 (EP,CN,US);
C07K2317/24 (EP,CN,US);
C07K2317/33 (EP,US);
C07K2317/34 (EP,CN,US);
C07K2317/55 (EP,CN,US);
C07K2317/565 (CN,US);
C07K2317/74 (EP,CN,US);
| C-Set: |
A61K39/3955, A61K2300/00 (CN)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/28] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | AUF DIE EC1-DOMÄNE VON CADHERIN-11 GERICHTETE HUMANISIERTE ANTIKÖRPER SOWIE ZUGEHÖRIGE ZUSAMMENSETZUNGEN UND VERFAHREN | [2018/28] | English: | HUMANIZED ANTIBODIES TARGETING THE EC1 DOMAIN OF CADHERIN-11 AND RELATED COMPOSITIONS AND METHODS | [2018/28] | French: | ANTICORPS HUMANISÉS CIBLANT LE DOMAINE EC1 CADHÉRINE-11 ET COMPOSITIONS ET PROCÉDÉS ASSOCIÉS | [2018/28] | Examination procedure | 27.03.2019 | Application deemed to be withdrawn, date of legal effect [2019/35] | 10.04.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2019/35] | Parent application(s) Tooltip | EP11741717.0 / EP2593128 | Fees paid | Renewal fee | 24.11.2017 | Renewal fee patent year 03 | 24.11.2017 | Renewal fee patent year 04 | 24.11.2017 | Renewal fee patent year 05 | 24.11.2017 | Renewal fee patent year 06 | 24.11.2017 | Renewal fee patent year 07 | 11.07.2018 | Renewal fee patent year 08 | 09.07.2019 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO9957149 (ADHEREX TECHNOLOGIES INC [CA], et al) [A] 1-4,7,12-14 * claims 16, 20 * * example 2 *; | [A]WO0117557 (BRIGHAM & WOMENS HOSPITAL [US]) [A] 1-4,7,12-14 * page 57, line 8 - line 15 *; | [A]WO2009101059 (NOVARTIS AG [CH], et al) [A] 1-4,7,12-14 * example 3 *; | [I]US2009253200 (MCARTHUR JAMES G [US]) [I] 1-4,7,12-14 * examples 6-8, 10-11 * * page 14, paragraph 0148 * * figure 20 * * paragraph [0056] * * paragraph [0069] * * paragraph [0071] - paragraph [0072] * * paragraph [0101] * * page 12; example 2 *; | [A] - MONAHAN T S ET AL, "A novel function for cadherin 11/osteoblast-cadherin in vascular smooth muscle cells: Modulation of cell migration and proliferation", JOURNAL OF VASCULAR SURGERY, C.V. MOSBY CO., ST. LOUIS, MO, US, vol. 45, no. 3, doi:10.1016/J.JVS.2006.12.016, ISSN 0741-5214, (20070301), pages 581 - 589, (20070222), XP022689755 [A] 1-4,7,12-14 * abstract * DOI: http://dx.doi.org/10.1016/j.jvs.2006.12.016 | [A] - LEE DAVID M ET AL, "Cadherin-11 in synovial lining formation and pathology in arthritis", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 315, no. 5814, doi:10.1126/SCIENCE.1137306, ISSN 1095-9203, (20070216), pages 1006 - 1010, (20070125), XP002528086 [A] 1-4,7,12-14 * page 1008, column r, paragraph 1 * * figures 3G-J * DOI: http://dx.doi.org/10.1126/SCIENCE.1137306 | [A] - VALENCIA XAVIER ET AL, "Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, (20041220), vol. 200, no. 12, doi:10.1084/JEM.20041545, ISSN 0022-1007, pages 1673 - 1679, XP002528085 [A] 1-4,7,12-14 * page 1675, column l, paragraph 2 * * figure 4 * DOI: http://dx.doi.org/10.1084/JEM.20041545 | [A] - KIENER HANS P ET AL, "Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro", AMERICAN JOURNAL OF PATHOLOGY; [10640], AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, (20060501), vol. 168, no. 5, doi:10.2353/AJPATH.2006.050999, ISSN 0002-9440, pages 1486 - 1499, XP002528084 [A] 1-4,7,12-14 * figure 6 * DOI: http://dx.doi.org/10.2353/AJPATH.2006.050999 | [A] - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOL, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20031101), vol. 21, no. 11, doi:10.1016/J.TIBTECH.2003.08.007, ISSN 0167-7799, pages 484 - 490, XP004467495 [A] 1-4,7,12-14 * page 485 - page 486 * DOI: http://dx.doi.org/10.1016/j.tibtech.2003.08.007 | by applicant | US4172124 | WO8601533 | EP0232262 | US4816567 | US4816397 | US4946778 | EP0125023 | EP0464533 | EP0519596 | WO9306213 | US5225539 | EP0120694 | EP0194276 | US5270163 | EP0239400 | US5399346 | US5440021 | US5475096 | EP0451216 | US5514548 | US5545806 | US5545807 | WO9713852 | - "Peptide Mimetic Design with the Aid of Computational Chemistry", DAMEWOOD J.R., Reviews in Computational Biology, John Wiley and Sons, Inc., (19960000), vol. 9, pages 1 - 80 | - MJ WHEELOCK; KR JOHNSON, Ann. Rev. Cell Dev. Biol., (20030000), vol. 19, pages 207 - 235 | - VALENCIA et al., J. Exp. Med., (20040000), vol. 200, no. 12, pages 1673 - 1679 | - KIENER; BRENNER, Arthritis Res Ther., (20050000), vol. 7, no. 2, pages 49 - 54 | - KIENER et al., Am. J. Pathol., (20060000), vol. 168 | - LEE et al., Science, (20070000), vol. 3i5, pages 1006 - 1010 | - KOHLER et al., Nature, (19750000), vol. 256, pages 495 - 497 | - Eur. J. Immunol., (19760000), vol. 6, pages 511 - 519 | - MILSTEIN et al., Nature, (19770000), vol. 266, pages 550 - 552 | - Current Protocols In Molecular Biology, John Wiley & Sons, (19910000), vol. 2 | - CHUNTHARAPAI et al., J. Immunol., (19940000), vol. 152, pages 1783 - 1789 | - NEWMAN, R. et al., BioTechnology, (19920000), vol. 10, pages 1455 - 1460 | - BIRD, R.E. et al., Science, (19880000), vol. 242, pages 423 - 426 | - KAMMAN, M. et al., Nucl. Acids Res., (19890000), vol. 17, page 5404 | - SATO, K. et al., Cancer Research, (19930000), vol. 53, pages 851 - 856 | - DAUGHERTY, B.L. et al., Nucleic Acids Res., (19910000), vol. 19, no. 9, pages 2471 - 2476 | - LEWIS, A.P.; J.S. CROWE, Gene, (19910000), vol. 101, pages 297 - 302 | - JAKOBOVITS et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 2551 - 2555 | - JAKOBOVITS et al., Nature, (19930000), vol. 362, pages 255 - 258 | - BENNETT et al., Journal of Molecular Recognition, (19950000), vol. 8, pages 52 - 58 | - JOHANSON et al., J. Biol. Chem., (19950000), vol. 270, no. 16, pages 9459 - 9471 | - Basic and Clinical Pharmacology, Appleton and Lange, pages 768 - 769,808-809,896 | - GANESAN, Drug Discov. Today, (20020100), vol. 7, no. 1, pages 47 - 55 | - LOU, Drug Discov. Today, (20011200), vol. 6, no. 24, pages 1288 - 1294 | - TUERK; GOLD, Science, (19900000), vol. 249, page 505 | - ELLINGTON; SZOSTAK, Nature, (19900000), vol. 346, page 818 | - HOET et al., Nature Biotechnology, (20050000), vol. 23, no. 3, pages 344 - 348 | - RAUCHENBERGER et al., J. Biol. Chem., (20030000), vol. 278, no. 40, pages 38194 - 38205 | - PATEL, SD et al., Cell, (20060000), vol. 124, pages 1255 - 1268 | - LEE et al., Science, (20070000), vol. 315, pages 1006 - 1010 | - TOCHILIN V.P., Annu Rev BiomedEng, (20060000), vol. 8, pages 343 - 375 | - "Recombinant DNA and Gene Transfer", Office of Biotechnology Activities, National Institutes of Health Guidelines | - Remington's Pharmaceutical Sciences, Mack Publishing Company | - VALENCIA et al., J. Exp. Med, (20040000), vol. 200, no. 12, pages 1673 - 1679 | - BRYSON C; JONES TD; BAKER MP., "Prediction of immunogenicity of therapeutic proteins: validity of computational tools", Biodrugs, (20100000), vol. 24, no. 1, doi:doi:10.2165/11318560-000000000-00000, pages 1 - 8, XP009178728 DOI: http://dx.doi.org/10.2165/11318560-000000000-00000 | - KORGANOW AS; JI H; MANGIALAIO S; DUCHATELLE V; PELANDA R; MARTIN T et al., "From systemic T cell self-reactivity to organ- specific autoimmune disease via immunoglobulins", Immunity, (19990000), vol. 10, doi:doi:10.1016/S1074-7613(00)80045-X, pages 451 - 61, XP000944280 DOI: http://dx.doi.org/10.1016/S1074-7613(00)80045-X | - GARCIA-VICUNA R; GOMEZ-GAVIRO M; DOMINGUEZ-LUIS M; PEC M; GONZALEZ-ALVARO M; ALVARO-GRACIA M; DIAZ-GONZALEZ F, Arth & Rheum, (20040000), vol. 50, pages 3866 - 3877 | - HASHIZUME M; HAYAKAWA N; MIHARA M, Rheumatology, (20080000), vol. 47, pages 1635 - 1640 |